Clinical trials: Circulating Tumor Cell;
Breast Cancer
Adjuvant Radiotherapy on Circulating Cells in Breast Cancer Patients
Radiation applied to the preserved breast during radiotherapy treatment activates numerous molecular cascades in tumor bed adjacent cells causing an inflammatory state.
- Trial name
- CCB-RT (NCT04002570)
- Testing
- blood samples collection
- Where
- Switzerland
- Volunteers
- 13 people
- Sponsor
- Clinica Luganese Moncucco
Colorectal Cancer Stage IV, Colorectal Cancer Metastatic
Plasma 5hmC Signatures as a Marker of Colorectal / Appendiceal Peritoneal Metastasis
Patients with peritoneal metastasis of colorectal or high grade appendiceal origin who are candidates for cytoreductive surgery with HIPEC (hyperthermic intraperitoneal chemotherapy) will be enrolled in this study.
- Conditions
- Colorectal Cancer Stage IV, Colorectal Cancer Metastatic, Colorectal Cancer, Genetics of, Appendix Cancer
- Trial name
- NCT04157322
- Testing
- prospective single arm biomarker (plasma cell-free DNA hydroxymethylation) study
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- University of Chicago
Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Efficacy Study of Herceptin to Treat HER2-negative CTC Breast Cancer
This is a randomized phase II trial for patients with HER2 negative primary Breast Cancer (BC) who after completing (neo) adjuvant chemotherapy and surgery have detectable circulating tumour cells (CTC) in peripheral blood.
- Conditions
- Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Circulating Tumor Cells
- Trial name
- TREAT-CTC (NCT01548677)
- Testing
- trastuzumab
- Where
- 80 sites in Belgium, France and 2 more
- Volunteers
- 1,317 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Metastatic Colorectal Cancer
Circulating Tumor Cells and Neutrophils Count for Colorectal Metastatic Cancer
Colorectal cancer represents a major public health problem in France because of its high incidence and severe prognosis. Early stages of the disease are well know and have justified the establishment of a mass screening strategy.
- Trial name
- NCT05793775
- Where
- 2 sites in France
- Volunteers
- 30 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Circulating Tumor Cell, HNSCC
Using a 3D Culture Model for Circulating Tumor Cells Combined With Molecular Bioassays in Patients With HNSCC Cancer
Cancer has been a significant cause of human death in the recent two decades, although detection, diagnosis, and cancer treatments improved and evolved rapidly.
- Trial name
- NCT06755762
- Testing
- Organoid 3D culture
- Where
- Taiwan
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Circulating Tumor Cells (CTCs), Immunotherapy
Predicting Clinical Efficacy of Immunotherapy Using Pre-treatment andContinuousMonitoring of PD-L1 TPS/CPS on CTCs, and Immunity Exhaustion Scores
Head and neck cancer is ranked among the fifth to eighth most prevalent cancers worldwide and is associated with a high mortality rate.
- Conditions
- Circulating Tumor Cells (CTCs), Immunotherapy, PD-L1 Expression, Liquidbiopsies
- Trial name
- NCT07396259
- Where
- Taiwan
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Breast Neoplasms
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
The main purpose of this study is to compare genetic markers present on tumor cells before and after chemotherapy.
- Trial name
- NCT00353483
- Testing
- Peripheral blood draw, Breast tissue collection, Bone marrow biopsy
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Washington University School of Medicine
Metastatic Head-and-neck Squamous-cell Carcinoma
Circulating Tumor Cells as an Early Predictive head-and -Neck Squamous-cell Carcinoma
In France, the incidence of head and neck squamous cell carcinomas (HNSCC) is 16 000 new cases/year. During these last years, many new chemotherapies and targeted therapies have been developed improving significantly the overall…
- Trial name
- CIRCUTEC (NCT02119559)
- Testing
- Blood analysis by EPISPOT and CellSearch®
- Where
- France
- Volunteers
- 115 people
- Sponsor
- University Hospital, Montpellier
Oropharynx Squamous Cell Carcinoma, Oropharynx Cancer
Circulating Biomarkers in Oropharyngeal Cancers
The goal of this observational longitudinal study is to learn about circulating tumor Human Papilloma Virus-DNA (ctHPV-DNA) as a biomarker for HPV positive oropharyngeal cancer and cancer of unknown primary of the head and neck.
- Conditions
- Oropharynx Squamous Cell Carcinoma, Oropharynx Cancer, Tonsillar Cancer, Base of the Tongue Carcinoma
- Trial name
- CIRCOS (NCT05904327)
- Where
- Sweden
- Volunteers
- 130 people
- Sponsor
- Region Örebro County
Pancreatic Cancer
Silicon Microsieve Device vs Cell Surface Marker-based Platform for the Isolation of Pancreatic Cancer CTCs
The study aims to compare the use of a microsieve device vs a cell surface marker-based platform for the isolation of pancreatic cancer circulating tumor cells
- Trial name
- NCT04638868
- Testing
- Microsieve device, Cell surface marker-based platform
- Volunteers
- 26 people
- Sponsor
- Singapore General Hospital
Squamous Cell Carcinoma of Oropharynx, HPV Positive Cancer
ctHPVDNA in HPV Positive Squamous Cell Carcinoma of the Oropharynx
This study is a prospective phase II trial, designed to assess the efficacy and feasibility of adjuvant treatment deintensification guided by ctHPVDNA levels for patients with HPV+OPSCC who undergo transoral surgery and neck…
- Conditions
- Squamous Cell Carcinoma of Oropharynx, HPV Positive Cancer, Throat Cancer, Tonsil Cancer
- Trial name
- NCT06915038
- Testing
- NavDx, Adjuvant Radiation 30 Gray, Adjuvant Radiation 40 Gray
- Where
- 2 sites in United States
- Volunteers
- 120 people
- Sponsor
- Indiana University
Lung Cancer, Lung Neoplasms
Isolating and Testing Circulating Tumor DNA and Soluble Immune Markers During the Course of Treatment for Lung Cancer
The purpose of this study is to explore the detection of circulating tumor DNA, soluble immune markers, and the evaluation of peripheral blood mononuclear cells (PBMC).
- Conditions
- Lung Cancer, Lung Neoplasms, Cancer of Lung, Cancer of the Lung
- Trial name
- NCT02410603
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Mayo Clinic
Neoplasms, Unknown Primary, Cancer
Molecular Analysis of Blood Samples in Standardized Cancer Care Referrals for SCAN and CUP
Patients with suspected cancer (SCAN) and cancer of unknown primary tumor (CUP) are vulnerable because the investigation is difficult and expensive and have poor prognosis because few effective established curative treatments are…
- Trial name
- NCT04025970
- Testing
- Circulating tumor cell and circulating tumor DNA test
- Where
- Sweden
- Volunteers
- 200 people
- Sponsor
- Christer Ericsson
Thoracic Surgery, Cardiopulmonary Bypass
Circulating Tumor Cells (CTC) Before and After Thoracic Resection With and Without Intraoperative Use of ExtraCorporeal Membrane Oxygenator(ECMO) or Cardio Pulmonary By Pass (CPB)
The role of circulating tumor cells (CTC) in patients suffering from lung cancer and thoracic malignancies is not well known and it is still widely debated.
- Trial name
- NCT04048512
- Testing
- Resection with intraoperative use of ECMO/CPB, Resection without intraoperative use of ECMO/CPB
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- European Institute of Oncology
Metastatic Breast Cancer, Breast Cancer
Clinical Utility of CTC Test in Medicare-Eligible Metastatic Breast Cancer Patients
The objective of the registry study is to demonstrate the clinical utility of the CELLSEARCH® CTC Test among the Medicare-Eligible metastatic Breast Cancer (mBC) patients in the United States.
- Trial name
- NCT02111031
- Where
- 2 sites in United States
- Sponsor
- Janssen Diagnostics, LLC
Non Small Cell Lung Cancer
Recurrence Monitoring in NSCLC Using Circulating Tumor DNA
This research study is investigating the role of cell free tumor DNA profiling in determining disease relapse and/or progression for patients with advanced NSCLC.
- Trial name
- NCT03878537
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Scripps Translational Science Institute
Glioblastoma Multiforme, Healthy Volunteers
Laboratory Study of Early Tumor Markers in the Peripheral Blood of Glioblastoma Multiforme Patients
The purpose of this study is to determine if tumor cells can be detected in the blood of patients diagnosed with a brain tumor.
- Trial name
- NCT01135875
- Testing
- GBM Patients, Normal Controls
- Where
- United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- University of Florida
Metastatic Non-small Cell Lung Cancer
Early Assessment of Response to Treatment of Metastatic LUng Tumors Based on CIrculating Tumor DNA
In patients with locally advanced or metastatic tumors, first-line therapeutic management is based on the use of targeted therapies (EGFR, BRAF ALK and ROS1 inhibitors), immunotherapies (anti-PD1/ anti-PDL1-antibodies or…
- Trial name
- ELUCID (NCT03926260)
- Testing
- ctDNA analysis
- Where
- 2 sites in France
- Volunteers
- 100 people
- Sponsor
- Centre Hospitalier Departemental Vendee
Neoplastic Cells, Circulating
The Detection of Circulating Tumor Cells (CTCs) in Patients With Liver Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment
Circulating tumor cells (CTCs) have the potential to provide a surrogate for'real-time biopsy' of tumor biological activity. Enumeration and molecular characterization of CTCs in liver cancer could play an important role in…
- Trial name
- NCT02416635
- Testing
- Flow cytometry (FCM), RT-PCR
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Cervical Cancer Stage IA1, Cervical Cancer Stage IB1
Research of Circulating Tumor Cells Released During Cervical Cancer Surgery
Cervical cancer is a rare pathology. Recent studies showed that the risk of recurrence is higher for patients treated by coelioscopy in comparison with laparotomy.
- Conditions
- Cervical Cancer Stage IA1, Cervical Cancer Stage IB1, Cervical Cancer Stage IA2, Cervical Cancer Stage IB2
- Trial name
- CTC-COL (NCT04770090)
- Testing
- Blood samples
- Where
- 3 sites in France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Montpellier